The findings of EXSCEL [13] and CANVAS programs [15] have not only confirmed the cardiovascular safety profiles of GLP-1 RAs and SGLT-2 inhibitors but also affected the recommendations on the personalised diabetes management in the ADA/EASD consensus statement [3]. The gene discussed is GCG; the disease is diabetes mellitus.